New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
06:14 EDTJNJ, BCS, DB, LYG, STD, JPM, DOW, AEG, RY, ING, RIMM, CS, UBS, BBVA, RBSOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Europe's program to defuse its financial crisis by injecting cash into the banking system is running out of energy as interest rates rise and some banks have little cash left, the Wall Street Journal reports...Dow Chemical (DOW) and other chemical companies see new opportunities in the enormous domestic deposits of gas, the Wall Street Journal reports...REUTERS: U.S. coal exports to China could more than double to over 12M tons in 2012 due to depressed freight rates and a decline in U.S. demand, says Xcoal Energy & Resources CEO Thrasher, Reuters reports...Johnson & Johnson (JNJ) received EU clearance to purchase Swiss medical device maker Synthes for about $21B, Reuters reports...BLOOMBERG: Research In Motion (RIMM) is close to deciding on a financial adviser, and JPMorgan Chase (JPM) is said to be the leading candidate to help the company weigh strategy options, Bloomberg reports.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 19, 2015
08:06 EDTDOWChemours agrees to sell aniline facility to Dow Chemical for $140M
Subscribe for More Information
November 18, 2015
10:34 EDTBCSBarclays to pay added $150M penalty over forex trading misconduct
Subscribe for More Information
08:55 EDTJPMMorgan Stanley exec sees Q4 not much better than Q3 for banks, DJ reports
Morgan Stanley (MS) Institutional Securities President Colm Kelleher cautioned that fixed-income markets "still seem subdued," according to Dow Jones, citing his comments at an investment conference. Morgan Stanley was among the banks that reported lower revenue from fixed-income, currency and commodities trading during the third quarter and Kelleher said he doesn't think "the fourth quarter is going to be much better," the report noted. Large bank peers to Morgan Stanley include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
06:54 EDTBCSBarclays eyes more investment bank cuts, Telegraph reports
Subscribe for More Information
06:01 EDTDOWMonsanto studying possibility for consolidation in agrochem sector, Reuters says
Subscribe for More Information
November 17, 2015
18:34 EDTJPM, RBSU.S. pursuing criminal charges against JPMorgan, RBS executives, WSJ says
Subscribe for More Information
18:16 EDTBCSBarclays set to pay at least $100M in new forex fine, FT says
Barclays is set to pay "at least" $100M by next month to settle allegations by the New York Department of Financial Services that the bank abused foreign exchange markets through its electronic trading platform, reports Financial Times, citing sources. Reference Link
09:02 EDTBCSAnalyst pans competing products, says buy Fitbit
Shares of previous high-flier Fitbit (FIT) have dropped about 30% in the last two weeks following the company's third quarter earnings report, but an analyst at Bank of America upgraded his view of the fitness tracker maker this morning, saying that now is the time to buy ahead of fourth quarter results that may be boosted by the "underwhelming" new products being launched by its competitors. UNDERWHELMING COMPETITION: Fitbit's sales guidance for this holiday quarter looks conservative, contends Bank of America analyst Nat Schindler, who notes that the company only had the launch of one new product last December but will have the Charge, Charge HR and Surge to drive sales this season. Schindler also notes that the company's international advertising has expanded into more countries ahead of the holidays this year. Key, however, may be the "underwhelming" lineup of new or updated fitness trackers launched by competitors, such as the Microsoft's (MSFT) Band 2, Jawbone's UP4 and Sony's (SNE) Smartband 2, many of which have only minor improvements and no "must have" features to pull consumers away from Fitbit, Schindler told investors in his research note. PLATFORM PICKING UP STEAM: The analyst also pointed out that Fitbit now has more than 20 companies signed onto its health and wellness platform, including big names like Target (TGT) and Barclays (BCS), which he believes should help drive revenue beats in the upcoming fiscal year due to increased device sales. Also, the additional dashboard data should help Fitbit maintain long-term user engagement, said Schindler. APPLE WATCH: Apple's (AAPL) Apple Watch is largely viewed as the biggest potential competitive threat to Fitbit's offerings, but on the fitness tracker maker's last earnings call CEO James Park said Fitbit's products differ from those of its competitors in several key aspects, including pricing, cross-platform compatibility, brand awareness and product line breadth. Other wearables makers include Garmin (GRMN) and Samsung. PRICE ACTION: Since the day after Fitbit's last earnings report after the market close on November 2, its shares have fallen about 29.5% to close yesterday at $28.80. In pre-market trading this morning, Fitbit shares rose 2% to $29.40.
08:34 EDTBCSNAREIT to hold a conference
Subscribe for More Information
07:50 EDTJPM, BCS, DBClearing House to hold a conference
Subscribe for More Information
07:48 EDTJPMBofa/Merrill to hold a conference
Banking & Financial Services Conference 2015 is being held in New York on November 17-18.
06:09 EDTUBSUBS to acquire SPB Italia, terms not disclosed, Reuters reports
Subscribe for More Information
November 16, 2015
17:10 EDTDOWSoros took stake in Paypal, liquidated Herbalife stake
Soros Fund Management gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Paypal (PYPL), CIT Group (CIT), Schlumberger (SLB), Kraft Heinz (KHC), and Amazon (AMZN). INCREASED STAKES: Allergan (AGN), Lions Gate (LGF), Energen (EGN), Southwest Airlines (LUV), and Qunar Cayman Islands (QUNR). DECREASED STAKES: LyondellBasell (LYB), YPF (YPF), Time Warner Cable (TWC), Dow Chemical (DOW), and Monsanto (MON). LIQUIDATED STAKES: Herbalife (HLF), Lennar (LEN), DR Horton (DHI), United Continental (UAL), and Nice Systems (NICE).
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information
11:24 EDTDB, JPM, BCSClearing House to hold a conference
Clearing House Annual Conference is being held in New York on November 16-18.
09:42 EDTJPMJPMorgan reports October net credit losses 2.22% vs. 2.21% last month
Subscribe for More Information
08:58 EDTJPMAmerican Express slips following Marriott, Starwood deal announcement
Shares of American Express (AXP) are slipping in pre-market trading following the news that Marriott (MAR) and Starwood Hotels & Resorts (HOT) have agreed to merge. In early June, American Express and Starwood announced new benefits to the Starwood Preferred Guest credit card. Marriott, however, has its co-brand program with JPMorgan Chase (JPM) and the early weakness in American Express shares could reflect concern over a potential change in the merged hotels' co-brand relationships. In pre-market trading, AxEx shares are down about 0.5% to $70.88.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use